- ICH GCP
- EU klinikai vizsgálatok nyilvántartása
Legfrissebb próbák
EudraCT Number: 2005-000290-22 | Sponsor Protocol Number: | Start Date: 2005-02-15 | ||||||
Sponsor Name: TÜ Kardioloogiakliinik | ||||||||
Full Title: Endoteeli funktsiooni hindamiskompleksi (pulsilaine analüüs, koronarograafia, immunohistokeemilised meetodid, biomarkerid) teaduslik väljatöötamine ja juurutamine kliinilises praktikas | ||||||||
Medical condition: | ||||||||
|
||||||||
Population Age: Adults | Gender: Male | |||||||
Trial protocol: EE (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000040-85 | Sponsor Protocol Number: HCC01 | Start Date: 2005-02-15 | ||||||
Sponsor Name: Medical School Hannover [...] 1. Medical School Hannover 2. Medical School Hannover | ||||||||
Full Title: Erbitux Monotherapie bei Patienten mit lokoregional nicht behandelbarem Hepatozellulären Karzinom | ||||||||
Medical condition: advanced hepatocellular carcinoma (hcc) not amandable to regional therapies or metastatic disease | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-003616-37 | Sponsor Protocol Number: M48P3 | Start Date: 2005-02-15 | ||||||
Sponsor Name: Chiron Behring GmbH & Co KG | ||||||||
Full Title: M48P3: A phase IV, randomized, controlled, single-blind, multi-center study in children to evaluate the safety, tolerability and immunogenicity of two TBE vaccines administered according to two dif... | ||||||||
Medical condition: TBE prophylaxis | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-003945-41 | Sponsor Protocol Number: N/A | Start Date: 2005-02-15 | ||||||
Sponsor Name: liverpool university | ||||||||
Full Title: Pharmacogenetics of GABAergic mechanisms of benefit and harm in epilepsy: : A prospective cohort study to determine the enviromental and genetic factors associated with response to clobazam. | ||||||||
Medical condition: Epilepsy | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-002143-27 | Sponsor Protocol Number: 1208.15 | Start Date: 2005-02-15 | ||||||
Sponsor Name: Boehringer Ingelheim Austria GmbH | ||||||||
Full Title: A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (... | ||||||||
Medical condition: Urge Urinary Incontinence (UUI) | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||
Trial protocol: AT (Completed) DK (Prematurely Ended) SE (Completed) DE (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-004201-18 | Sponsor Protocol Number: 0881A-101696 | Start Date: 2005-02-15 | ||||||
Sponsor Name: Wyeth Lederle Nordiska AB | ||||||||
Full Title: A multicenter, open-label, randomized, pilot study to evaluate the efficacy and safety of the combination of etanercept (ETN) and methotrexate and of etanercept (ETN) alone in patients with active ... | ||||||||
Medical condition: Plaque psoriasis | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: FI (Completed) DK (Completed) SE (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-001183-41 | Sponsor Protocol Number: D5899C00002 | Start Date: 2005-02-14 | |||||||||||
Sponsor Name: AstraZeneca AB | |||||||||||||
Full Title: A 6-month, double-blind, double-dummy, randomised, parallel group, multicenter, efficacy and safety study of Symbicort® pMDI 2x160/4.5μg and 2x80/4.5μg bid compared to Formoterol Turbuhaler, Budes... | |||||||||||||
Medical condition: This is an application for a phase III study to be conducted in COPD patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002341-12 | Sponsor Protocol Number: DEB-EPI-206 | Start Date: 2005-02-14 | |||||||||||
Sponsor Name: Debiopharm SA | |||||||||||||
Full Title: Multicenter, 8-week, Randomised, Double-Blind, Placebo Controlled Study of Two Doses of Depelestat in Cystic Fibrosis Patients | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) IT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004801-11 | Sponsor Protocol Number: 04-081 | Start Date: 2005-02-14 | ||||||
Sponsor Name: Zealand Pharma A/S | ||||||||
Full Title: A Phase II, Multicenter, Double-Blind, Efficacy, Safety, and Tolerability Study of ZP120 Administered as Short Term I.V. Infusion as Add-On Therapy in Patients with Subacute Decompensated Chronic H... | ||||||||
Medical condition: Subacute decompensated chronic heart failure NYHA Class III-IV | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: DK (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001754-92 | Sponsor Protocol Number: AAE581C2201 | Start Date: 2005-02-14 | ||||||
Sponsor Name: Novartis Pharma Services AG | ||||||||
Full Title: A phase II, 12-month, double-blind, placebo-controlled, dose-finding, multicenter study to evaluate the safety, tolerability, and disease modifying efficacy of daily oral AAE581 (10, 25 and 50 mg t... | ||||||||
Medical condition: Osteoarthritis (OA) is a disease with a complex pathophysiology leading to the degeneration of articular cartilage and bone. It is characterized by pain, biochemical and enzymatic changes, cartilag... | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) IT (Completed) | ||||||||
Trial results: View results |